Connect your AI

Ardelyx ARDX Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

AmgenAMGN

——

Bausch Health CompaniesBHC

——

Neurocrine BiosciencesNBIX

——

Aurinia PharmaceuticalsAUPH

——

Agios PharmaceuticalsAGIO

——

Other financials

Income statement

Revenue$94.5M+27.5%

Gross profit$89.7M+45.1%

Operating income-$32.8M+9.8%

Net income-$37.6M+8.6%

EPS (diluted)-$0.15+11.8%

Balance sheet

Cash & equivalents$31.2M+1.3%

Total debt$208.3M+34.3%

Total equity$148.6M+2.0%

Total assets$504.5M+23.0%

Cash flow

Operating cash flow-$32.2M+16.2%

CapEx$69.0K-78.8%

Free cash flow-$32.3M+16.7%

Valuation

Market cap$1.53B+79.5%

Enterprise value$1.71B+74.8%

P/S3.6×+1.2×

Profitability

Gross margin92.5%+7.9pp

Operating margin-25.4%—

Net margin-13.6%—

FCF margin-40.9%—

Returns & leverage

Return on equity-39.5%—

Debt / equity1.4×+0.3×

Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ardelyx's remainder of fiscal year 2024?: Ardelyx (ARDX) reported remainder of fiscal year 2024 of $1.34M in Q1 2026.
How has Ardelyx's remainder of fiscal year 2024 changed year-over-year?: Ardelyx's remainder of fiscal year 2024 increased by 17.2% year-over-year, from $1.15M to $1.34M.